… ) and a trend for association of dose with risk of heart failure (P = 0.069; this analysis was
adjusted … and in that relative to dose versus risk of heart failure (controlled for age), there was a …

Xanthine oxidoreductase (XOR) is the rate-limiting enzyme in purine catabolism and converts
hypoxanthine to xanthine, and xanthine into uric acid. When concentrations of uric acid …

… There was a negative correlation between XOR activity and eGFR in patients with chronic
heart failure [31]. The present study also showed a negative statistical correlation between …

… While the enzymatic activity of PON1 in the cardiac tissue significantly increased after oral
… In contrast, the specific activity of the cardiac XO noted a significant reduction in the propolis …

… of the XOR substrate xanthine significantly altered the … activity. Furthermore, examination
of the influence of the age (young cells vs. old cells) of human RBCs on XO activity also failed to …

… with cardiovascular diseases, including ischemic heart disease and heart failure, as well as
… risk factor for hypertension and ischemic heart disease and heart failure, after an extensive …

… The latter can also be accompanied with an increased expression of sialin (ie NO 3 −
transporter) to maintain skeletal muscle N-oxides, which combined may help to maintain NO …

… by the report showing that a XOR inhibitor, allopurinol, but not a uricosuric accelerator,
probenecid, is shown to improve endothelial function in patients with heart failure [46]. Thus, XOR …

… We hypothesized that carotid plaques from symptomatic patients are characterized by an
increased expression of XO, which would be related to cardiovascular risk factors and serum …

… The aim of the present study was to reveal the effect of a xanthine oxidoreductase (XOR)
inhibitor, topiroxostat (Top), compared with another inhibitor, febuxostat (Feb), in an adenine-…